Publication|Videos|January 26, 2024
At AAPS with CritiTech Particle Engineering Solutions
Matthew McClorey, President of CritiTech Particle Engineering Solutions, shares his insights at AAPS.
At a recent American Association of Pharmaceutical Scientists (AAPS) convention, BioPharm International sat down with Matthew McClorey, President of CritiTech Particle Engineering Solutions.
Learn more about:
- What makes CritiTech unique in the CDMO market.
- What you can expect from working with CritiTech.
- The company’s ability to formulate direct-to-site treatments from previously systemically delivered drugs with the patented Purcision platform.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
How CDMO Alliances Can Provide End-to-End Service that Reduces Drug Development Time and Costs
2
First-in-Human Study Validates Safety of Next-Generation mRNA–LNP Platform
3
FDA Clears PharmaResearch IND for Nano-Based Cancer Drug PRD-101
4
Industry Outlook 2026: Key Forces Transforming Drug Pipelines (Part 2)
5